openPR Logo
Press release

Exploring the Advancements in Familial Mediterranean Fever Clinical Trials: Anticipating the Arrival of 3+ Innovative Therapies into the Landscape, Insights by DelveInsight

01-12-2024 06:05 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Familial Mediterranean Fever Pipeline

Familial Mediterranean Fever Pipeline

(Albany, USA) DelveInsight's report titled "Familial Mediterranean Fever Pipeline Insight" offers extensive information on more than 3+ companies and over 3+ pipeline drugs in the field of Familial Mediterranean Fever research. The report encompasses detailed profiles of the pipeline drugs for Familial Mediterranean Fever, including information on clinical trials and nonclinical stage products.

For the Familial Mediterranean Fever emerging drugs, the pipeline analysis report presents a comprehensive view of the therapeutic landscape, considering the development stage, product type, and route of administration, molecule type, and mechanism of action (MOA). The research on the Familial Mediterranean Fever pipeline covers various aspects such as business opportunities, challenges, potential partnerships, strong competitors, and growth strategies.

To explore more information on the latest breakthroughs in the Familial Mediterranean Fever Pipeline treatment landscape of the report, click here @ Familial Mediterranean Fever Pipeline Outlook- https://www.delveinsight.com/report-store/familial-mediterranean-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Familial Mediterranean Fever Pipeline Report
• DelveInsight's Familial Mediterranean Fever Pipeline analysis depicts a robust space with 3+ active players working to develop 3+ pipeline treatment therapies.
• The leading Familial Mediterranean Fever Companies are working in the market include Roche, Novartis, Bellus Health nc, AbbVie, Eisai, Amgen, and others.
• Promising Familial Mediterranean Fever Pipeline Therapies in various stages of development include Canakinumab (AIN457), Canakinumab, NC-503 (Anti-amyloidotic (AA) Agent), Adalimumab, ACZ885, Apremilast, and others
• Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions.
• On Feb 2023, R-Pharm International announced a long-term open-label study is an extension of the core double blind, randomized, placebo-controlled study, CL04018065. It is planned that this study will include no more than 60 patients who completed the core study, where they received blinded therapy.

Familial Mediterranean Fever Overview
Familial Mediterranean fever (FMF) is an inherited auto inflammatory disease characterized by recurrent episodes (attacks) of fever and acute inflammation of the membranes lining the abdomen, joints, and lungs. Some individuals may develop a serious condition known as amyloidosis, in which certain proteins called amyloid accumulates in various tissues of the body.

For further information, refer to the detailed Familial Mediterranean Fever Unmet Needs, Familial Mediterranean Fever Market Drivers, and Familial Mediterranean Fever Market Barriers, click here for Familial Mediterranean Fever Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/familial-mediterranean-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Familial Mediterranean Fever Emerging Drugs Profile
• Tocilizumab: Roche

Familial Mediterranean Fever Pipeline Therapeutics Assessment
There are approx. 3+ key companies which are developing the therapies for Familial Mediterranean Fever. The companies which have their Familial Mediterranean Fever drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Roche and others.

Request a sample and discover the recent advances in Familial Mediterranean Fever Ongoing Clinical Trial Analysis and Medications, click here @ Familial Mediterranean Fever Treatment Landscape- https://www.delveinsight.com/sample-request/familial-mediterranean-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Familial Mediterranean Fever Pipeline Therapeutics Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Some of the Companies in the Familial Mediterranean Fever Therapeutics Market include-
Roche, Novartis, Bellus Health nc, AbbVie, Eisai, Amgen, and others

Dive deep into rich insights for drugs for Familial Mediterranean Fever Pipeline, click here @ Familial Mediterranean Fever Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/familial-mediterranean-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Familial Mediterranean Fever Pipeline Report
• Coverage- Global
• Familial Mediterranean Fever Companies- Roche, Novartis, Bellus Health nc, AbbVie, Eisai, Amgen, and others.
• Familial Mediterranean Fever Pipeline Therapies- Canakinumab (AIN457), Canakinumab, NC-503 (Anti-amyloidotic (AA) Agent), Adalimumab, ACZ885, Apremilast, and others.
• Familial Mediterranean Fever Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Familial Mediterranean Fever Mergers and acquisitions, Familial Mediterranean Fever Licensing Activities @ Familial Mediterranean Fever Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/familial-mediterranean-fever-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Introduction
2. Familial Mediterranean Fever Executive Summary
3. Familial Mediterranean Fever: Overview
4. Familial Mediterranean Fever Pipeline Therapeutics
5. Familial Mediterranean Fever Therapeutic Assessment
6. Familial Mediterranean Fever - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Familial Mediterranean Fever Collaboration Deals
9. Late Stage Products (Phase III)
10. Drug profiles in the detailed report…..
11. Mid Stage Products (Phase II)
12. Tocilizumab: Roche
13. Drug profiles in the detailed report…..
14. Pre-clinical and Discovery Stage Products
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Familial Mediterranean Fever Key Companies
18. Familial Mediterranean Fever Key Products
19. Familial Mediterranean Fever- Unmet Needs
20. Familial Mediterranean Fever- Market Drivers and Barriers
21. Familial Mediterranean Fever- Future Perspectives and Conclusion
22. Familial Mediterranean Fever Analyst Views
23. Familial Mediterranean Fever Key Companies
24. Appendix

Latest Reports launched by DelveInsight:
• Foot And Ankle Devices Market: https://www.delveinsight.com/report-store/foot-and-ankle-devices-market
• Hepatitis B Virus Market: https://www.delveinsight.com/infographics/chronic-hepatitis-b-virus-market
• Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Alopecia Aerata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Pressure Ulcers Market Size: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Alopecia Areata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Brain/cranial Implants Market: https://www.delveinsight.com/report-store/brain-implants-market-market
• Global Electrophysiology Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Hemodynamic Monitoring Systems Market: https://www.delveinsight.com/report-store/hemodynamic-monitoring-system-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Parkinson's Disease Market: https://www.delveinsight.com/report-store/parkinsons-disease-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Energy Based Aesthetic Devices Market: https://www.delveinsight.com/report-store/energy-based-aesthetic-devices-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Scleroderma Market: https://www.delveinsight.com/report-store/scleroderma-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Hyperuricemia Market: https://www.delveinsight.com/report-store/hyperuricemia-pipeline-insight
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market

Contact Us:
Ankit Nigam
Assistant Manager Marketing
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/consulting

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Exploring the Advancements in Familial Mediterranean Fever Clinical Trials: Anticipating the Arrival of 3+ Innovative Therapies into the Landscape, Insights by DelveInsight here

News-ID: 3350064 • Views:

More Releases from DelveInsight Business Research

Lassa Fever Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Inovio Pharmaceuticals, Irrua Specialist Teaching Hospital, Bernhard Nocht Institute for Tropical Medicine
Lassa Fever Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FD …
The Lassa Fever market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lassa Fever pipeline products will significantly revolutionize the Lassa Fever market dynamics. DelveInsight's "Lassa Fever Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Lassa Fever, historical and forecasted epidemiology as well as the Lassa Fever market trends in the United
Alcohol Use Disorder Pipeline Review, 2024 Updates | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Alkermes, Teva Pharmaceutical Industries Ltd., BioCorRx, Inc., Adial Pharmaceuticals, ADDEX TH
Alcohol Use Disorder Pipeline Review, 2024 Updates | Latest FDA, EMA, and PMDA A …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Alcohol Use Disorder pipeline constitutes 30+ key companies continuously working towards developing 30+ Alcohol Use Disorder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Alcohol Use Disorder Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alcohol Use
Dystrophic Epidermolysis Bullosa Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Berg Pharma, Holostem Terapie Avanzate, Aegle Therapeutics, RegeneRx B
Dystrophic Epidermolysis Bullosa Pipeline Drugs Analysis Report, 2024 Updates: F …
Dystrophic Epidermolysis Bullosa pipeline constitutes 15+ key companies continuously working towards developing 15+ Dystrophic Epidermolysis Bullosa treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Dystrophic Epidermolysis Bullosa Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dystrophic Epidermolysis Bullosa Market. The Dystrophic Epidermolysis Bullosa Pipeline report embraces in-depth commercial and
Non-Hodgkin Lymphoma Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Approvals, Therapies and Key Companies involved by DelveInsight | AstraZeneca, Baxter, Bayer, Bristol Myers Squibb, Teva Pharma, Eli Lilly, Roche
Non-Hodgkin Lymphoma Pipeline and Clinical Trials Assessment, 2024 Updates: FDA …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Non-Hodgkin Lymphoma pipeline constitutes 200+ key companies continuously working towards developing 220 + Non-Hodgkin Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Non-Hodgkin Lymphoma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Hodgkin Lymphoma Market. The

All 5 Releases


More Releases for Familial

Familial Adenomatous Polyposis (FAP) Therapeutics- Pipeline Analysis 2018
Familial adenomatous polyposis (FAP) is a genetic disorder, characterized by the development of adenomatous colon polyps in the intestinal tract, resulting in colon cancer. The disease is diagnosed when more than 100 adenomatous colon polyps are developed in a person. Download the sample report at: https://www.pharmaproff.com/request-sample/1025 A person with FAP is at a high risk of developing cancer of small intestines or stomach. This disease is categorized into three types including attenuated
Familial Amyloid Cardiomyopathy Treatment Market Opportunity Analysis, 2018–20 …
Aggregation and deposition of mutant and wild-type transthyretin protein (TTR) in heart results in familial amyloid cardiomyopathy, which typically occur after age of 60. Familial amyloid cardiomyopathy is also known as hereditary cardiac transthyretin amyloidosis or hereditary amyloid cardiomyopathy. The protein transthyretin amyloid fibrils infiltrate the myocardium that leads to diastolic dysfunction from restrictive cardiomyopathy, which eventually result to heart failure. There are several mutation in TTR which are associated
Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H2 2017
Market Research Hub's latest Pharmaceutical and Healthcare disease pipeline guide “Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review”, H2 2017, provides an overview of the Heterozygous familial hypercholesterolemia (heFH) (Metabolic Disorders) pipeline landscape. Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder caused due to a mutation (alteration) of FH from one (affected) parent. Symptoms include xanthesmas, corneal arcus, aortic rupture and peripheral vascular disease. Risk factors include age, sex, smoking and hypertension,
Familial Adenomatous Polyposis - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Familial Adenomatous Polyposis - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Familial Adenomatous Polyposis - Pipeline Review, H2 2017, provides an overview of the Familial Adenomatous Polyposis (Genetic Disorders) pipeline landscape. Familial adenomatous polyposis (FAP) or classic FAP is a genetic condition that causes extra
Familial Chylomicronemia Syndrome Treatment Market
Familial Chylomicronemia Syndrome is a genetic condition characterized by an inability of the body to digest fats mainly triglyceride. In Familial Chylomicronemia Syndrome, the lipoprotein lipase (LPS) is not functional, which is the enzyme that breaks down chylomicrons in the blood. The most distinctive sign of Familial Chylomicronemia Syndrome is the appearance of fatty blood on the skin, mainly owing to high level of fat in the body. People with
Familial Adenomatous Polyposis - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Familial Adenomatous Polyposis - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Familial Adenomatous Polyposis - Pipeline Review, H1 2017, provides an overview of the Familial Adenomatous Polyposis (Genetic Disorders) pipeline landscape. Familial adenomatous polyposis (FAP) is also known as familial polyposis coli, adenomatous polyposis coli, or